Drug Profile
Budesonide/formoterol - MAP Pharmaceuticals
Alternative Names: MAP 0005Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan
- 25 May 2012 Budesonide/formoterol - MAP Pharmaceuticals is available for partnering in World as of 25 May 2012. http://www.mappharma.com